Biodesix, Inc.

NASDAQ:BDSX

Medical - Diagnostics & Research

Healthcare
$8.40 +13.40%

+$2.04 today

Market cap
$68.38M
Beta
0.59
P/E (TTM)
-5.2
EPS (TTM)
-$3.31
52W Low $5.00High $20.21

Volume 0.17M

Average 0.06M

BDSX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Biodesix, Inc.NASDAQ: BDSX

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 83.5%

Gross margin was 83.5% in Q1 FY2026, up 4.2 pp from a year earlier. On a trailing-twelve-month basis it was 82.1%, up 3.7 pp year over year. Over 3 fiscal years it widened by 18.1 pp.

Context

  • Gross margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
83.5%+0.5 pp QoQ
Last fiscal yearDec 2025
81.1%+2.9 pp YoY
LTMMar 2026
82.1%+3.7 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+4.2 pp——
1 year+2.9 pp——
3 years+18.1 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
81.1%
Year-over-year change
+2.9pp

Gross Margin vs competitors

How BDSX compares with its peers on the latest reported figures

  • BDSX's LTM Mar 2026 gross margin of 82.1% is the 2nd highest of the 3 companies compared; the peer median is 85.3%.
  • Its year-over-year change of +3.7 pp is the highest of 3, against a peer median of -14.7 pp.
  • Over three fiscal years its change of +18.1 pp compares with a peer median of +0.0 pp.
BDSX Competitors Peer median
Gross Margin for BDSX and competitors
Company Period LTM level YoY 3-year change
INMBINmune Bio, Inc.FY2025100.0% +0.0 pp+0.0 pp
BDSXBiodesix, Inc.LTM Mar 202682.1% +3.7 pp+18.1 pp
XLOXilio Therapeutics, Inc.LTM Mar 202670.7% -29.3 pp—
OKUROnKure Therapeutics, Inc.FY2025— ——
PDSBPDS Biotechnology CorporationFY2025— ——
Peer median (excluding BDSX) 85.3%-14.7 pp+0.0 pp

Competitors are the stored peer set for BDSX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue54.51M38.21M49.09M71.32M88.5M
Cost of Revenue30.52M14.15M13.01M15.57M16.72M
Gross Profit23.99M24.06M36.08M55.75M71.78M
Gross Margin44.0%63.0%73.5%78.2%81.1%
Research & Development12.79M13.1M9.99M9.56M12M
Selling, General & Admin50.52M61.46M67.39M80.45M87.55M
Operating Expenses64.93M74.65M77.42M90.25M99.55M
Depreciation & Amortization3.18M5.84M5.51M5.46M5.6M
EBITDA(35.47M)(51.53M)(37.1M)(29.22M)(21.95M)
EBITDA Margin-65.1%-134.9%-75.6%-41.0%-24.8%
Operating Income(40.94M)(50.59M)(41.34M)(34.5M)(27.77M)
Operating Margin-75.1%-132.4%-84.2%-48.4%-31.4%
Interest Income00000
Interest Expense4.51M8.07M9.54M8.26M7.72M
Other Income / Expenses(2.22M)(14.86M)(10.8M)(8.43M)(7.5M)
Income Before Tax(43.16M)(65.45M)(52.15M)(42.93M)(35.27M)
Pre-Tax Margin-79.2%-171.3%-106.2%-60.2%-39.8%
Income Tax Expense00000
Net Income(43.16M)(65.45M)(52.15M)(42.93M)(35.27M)
Net Margin-79.2%-171.3%-106.2%-60.2%-39.8%
EPS (Basic)(31.60)(31.00)(12.80)(6.60)(4.67)
EPS (Diluted)(31.60)(31.00)(12.80)(6.60)(4.67)
Weighted Avg Shares1.37M2.11M4.11M6.48M7.55M
Weighted Avg Shares (Diluted)1.37M2.11M4.11M6.48M7.55M

Biodesix, Inc.

NASDAQ:BDSX

Intrinsic Alpha fair value

Locked

Current Price

$8.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.